Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047697 · ClinicalTrials.gov registry record · Phase 2
Donepezil HCl & Cognitive Deficits in Autism
A Phase 2 study of Autistic Disorder, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT00047697: Completed Phase 2 study of Autistic Disorder, sponsored by University of Pittsburgh.
NCT00047697 is a Phase 2 study of Autistic Disorder that has completed, run by University of Pittsburgh. The registered enrollment target is 34 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047697, a Phase 2 study of Autistic Disorder, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.
Primary Outcome
TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donepezil HCl
Study Locations (1)
Pennsylvania
- Western Psychiatric Institute & Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00047697 record still lists
NCT00047697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00047697 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00047697 about?
NCT00047697 is a clinical study titled "Donepezil HCl & Cognitive Deficits in Autism". This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.
What is the current status of trial NCT00047697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2002-10. Estimated completion is 2006-08.
What conditions does trial NCT00047697 study?
This clinical trial studies the following conditions: Autistic Disorder.
What interventions are being tested in trial NCT00047697?
The interventions under investigation include: Placebo (DRUG), Donepezil HCl (DRUG).
Who is sponsoring clinical trial NCT00047697?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047697 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047697's enrollment target sits among peer trials
34 24th of 27 higher than 4 of 27 other Autistic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autistic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
COMPLETED · Phase 2
-
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia